U.S. FDA says Empowered Diagnostics recalling COVID-19 tests

Jan 28 (Reuters) - Empowered Diagnostics LLC is recalling its COVID-19 tests as they have not been cleared for use in the United States and could potentially lead to false results, the U.S. Food and Drug Administration (FDA) said on Friday.

The regulator has labeled the recall of the CovClear COVID-19 rapid antigen test and the ImmunoPass COVID-19 neutralizing antibody rapid test as Class 1, or the most serious type of recall.

It cautioned people to stop using the two tests, which have been distributed with labeling that incorrectly indicates that they are authorized by the FDA.

The company could not be immediately reached for comment.

Empowered Diagnostics initiated the recall in December and has pulled back at least 284,575 antigen tests and 2,100 antibody tests in the United States, according to the regulator.

The CovClear test is currently authorized in Canada and the European Union, according to the company's website.

(Reporting by Amruta Khandekar; Editing by Devika Syamnath)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.